Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest drug manufacturer, has announced an investment of ₹3,800 crore in the state.
The move will generate over 2,000 direct and indirect jobs, reinforcing the state’s emergence as a preferred destination for pharma and biotech investments.
The announcement was made during the Madhya Pradesh Global Investors Summit (MP-GIS), where Chief Minister Mohan Yadav unveiled a record ₹26.6 trillion worth of investment proposals across sectors, with pharmaceuticals playing a key role.
Expansion of Manufacturing and R&D Capabilities
Sun Pharma’s investment will be directed toward upgrading existing manufacturing units in Dewas and Malanpur, which were acquired through its $4 billion acquisition of Ranbaxy Laboratories in 2014.
The company also plans to establish a state-of-the-art R&D facility, aimed at accelerating innovation in generics, biosimilars, and specialty drugs.
The Dewas site, previously flagged by the US FDA for compliance issues under Ranbaxy, is undergoing significant modernization.
Sun Pharma has committed to enhancing quality standards, automating production lines, and integrating AI-driven analytics to meet global regulatory benchmarks.
Sun Pharma Strategic Alignment with State’s Growth Vision
Madhya Pradesh’s government has introduced lucrative industrial policies to attract pharmaceutical companies.
These include land subsidies, single-window clearances, and tax incentives.
According to Dr. Viranchi Shah, President of the Indian Drug Manufacturers Association (IDMA), the state is poised to attract ₹4,000–₹4,500 crore in pharma investments over the next five years.
Chief Minister Mohan emphasized that the state’s geographical advantage, skilled workforce, and stable governance make it ideal for long-term industrial growth.
He added that Sun Pharma’s investment supports the state’s employment objectives.
It contributes to Madhya Pradesh’s goal of creating 1.73 million jobs through the MP-GIS commitments.
Public-Private Collaboration for Health Innovation
Sun Pharma has partnered with the Indian Council of Medical Research (ICMR) and the Madhya Pradesh government to support malaria eradication efforts.
This collaboration highlights the company’s commitment to public health and social impact.
The new R&D facility will support the Make in India and Innovate in India missions. Madhya Pradesh will serve as a strategic hub for these national initiatives.
Note: We are also on WhatsApp, LinkedIn, Google News, and YouTube, to get the latest news updates. Subscribe to our Channels. WhatsApp– Click Here, Google News– Click Here, YouTube – Click Here, and LinkedIn– Click Here.
